155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent/metastatic HNSCC: Preliminary safety data from AHEAD-MERIT. (December 2022) - Klinghammer, K.; Saba, N.F.; Castelluci, E.; Colevas, A.D.; Rutkowski, T.; Greil, R.; Thurner, D.; Müller-Richter, U.; Di Giacomo, A.M.; Grewal, J.; Ottensmeier, C.H.H.; Atasoy, A.; et al.